In summary, we believe M1i-124 and M1i-124d1 are first-in-class BCL10-MALT1 PPI inhibitors that demonstrate preclinical efficacy in selectively suppressing the proliferation and survival of MALT1-dependent ABC-DLBCL. This evidence concerns the gene BCL10 and aneurysmal bone cyst.